Previously writing on antibody contract research organisation Fusion Antibodies (FAB), last month I noted the shares rising from 45p on an “R&D update”, but wrote attempted ramptastic?, how “sufficient” is the cash now?. Today a “trading statement” and the shares currently more than 30% lower towards 30p.
Previously writing on antibody contract research organisation Fusion Antibodies (FAB), in August with the shares rising above 100p I wrote ‘ramptastic patent application announcement, cash sufficient for current requirements?’. The shares have since slumped to most recently close at 45p, but what of an announcement today taking them up currently more than 5.5%?
Fusion Antibodies (FAB) has announced it “continues to work on next generation antibody discovery, and we see significant opportunities in this field… has submitted a patent application in respect of the company's bispecific designs for antigen display”. What of a current approaching 15% share price rise on the back of this to above 100p?
Fusion Antibodies (FAB) has announced a trading update for its year ended 31st March 2022 and that “the number of customer enquiries being received for all of the company's services remains strong, and in H2 of FY2022 the company strengthened its commercial team”. So what of a current 67p share price?...
On 21st February Fusion Antibodies (FAB) announced the resignation of CEO Richard Jones, though stating “Richard will remain with the company while arrangements are put in place for his successor. The board has initiated a formal search for a new CEO”. It has today announced that “Richard Jones has now stepped down from his role as CEO, effective from 11 March 2022”. Who’s the successor then?…
Fusion Antibodies (FAB), “specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, notes the recent movement in the company's share price”. By “recent movement” it means fall from 96p at the start of this month to a last close 82.5p. So what’s the reason?...
Antibody contract research organisation Fusion Antibodies (FAB) has announced results for its half-year ended 30th September 2021 emphasising “20% underlying growth in revenues over H1 FY2021… and in particular the two major contracts which were secured which, taken together with the remaining pipeline of projects with other customers, give the board confidence that revenues for the full year will be in line with current expectations”. However, what is the financial impact of the revenue and what are the full year expectations?...
Fusion Antibodies (FAB) has announced results for its year ended 31st March 2021 emphasising “significant progress with sustained revenue growth, progress on the R&D pipeline, and continue to expand our range of services”. So why are the shares, at 125p, currently more than 7% lower in response?...
